HLS Therapeutics Reports Annual Meeting Results

TORONTO, June 25, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces voting results for the election of directors at its Annual Meeting of Shareholders held on June 22, 2018 in Toronto, Ontario.

A total of 22,700,718 Common Shares, or 82.76% of the total Common Shares issued and outstanding, were voted in connection with the meeting. Based on proxies received prior to the meeting and votes cast in person at the meeting, each director nominee was elected by a substantial majority as follows:

Nominees	Votes For	% For	Votes Withheld	% Withheld
William Wells	22,406,001	99.95%	11,431	0.05%
Greg Gubitz	22,405,998	99.95%	11,434	0.05%
J. Spencer Lanthier	22,399,613	99.92%	17,819	0.08%
Yvon Bastien	22,400,444	99.92%	16,988	0.08%
Rodney Hill	22,400,679	99.93%	16,753	0.07%
Don DeGolyer	22,400,274	99.92%	17,158	0.08%
Daniel Tasse	22,400,679	99.93%	16,753	0.07%

 

Shareholders also voted in favour of the Company's stock option incentive plan and the appointment of Ernst & Young LLP as its auditors.  

About HLS Therapeutics Inc.

HLS (TSXV: HLS) is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established, branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is comprised of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE HLS Therapeutics Inc.

Copyright 2018 Canada NewsWire